Novo Holdings led a USD125m Series C for Hummingbird Bioscience, a Singapore- and US-based clinical stage developer of targeted therapeutics, with participation from Frazier Healthcare Partners, Octagon Capital, EDBI, AMGEN Ventures, DROIA Ventures, Morningside Ventures, Pureos Bioventures, Polaris Partners, Affinity Asset Advisors, Ally Bridge Group and Altrium Capital Management, and follow-on from SK Inc, Heritas Capital, Mirae Asset Venture Capital and and SEEDS Capital. Read more